Startseite » Institut » Frey-Werle-Stiftung


Frey-Werle Foundation



A sense of tradition, combined with the concentration of research activities on the kallikrein-kinin system in Munich connected with other notable kinin centres worldwide, kept the memory of the two scientists from the University of Munich, Emil-Karl Frey and Eugen Werle, alive in the scientific community and has led to the establishment of the 'E.K. Frey-E. Werle Foundation of the Henning L. Voigt Family' in 1988.

The surgeon Emil-Karl Frey, a scholar of the famous ‘Geheimrat’ Ferdinand Sauerbruch, observed in 1925 a considerable reduction in arterial blood pressure when he injected human urine into dogs. Unlike many other contemporary scientists he did not attribute this effect to a toxic action of urine, but rather as the specific activity of an unknown substance with potential biological functions (Frey, 1926; Frey and Kraut, 1926): “It is a substance that probably originates from several organs, is eliminated by the kindneys and has a pronounced cardioactive and vasoactive effect: a substance that is assigned the role of a hormone in the organism”. This F-substance was then called kallikrein, since it was considered to have originated in the pancreas (Greek synonym: kallikreas) (Kraut et al, 1930).

Ten years later, Eugen Werle (Werle et al., 1937) identified kallikrein as a proteolytic enzyme (‘ferment’) that liberates the biologically highly active, basic polypeptide ‘DK’ or kallidin (i.e lys-bradykinin) from a blood plasma protein called kallidinogen or kininogen (H- and L-kininogen). Hence, kallidin was the first of the basic peptides formed by proteolysis to be identified as a hormone, and later became known as lys-bradykinin, a member of the family of biologically active kinin peptides. Kallidin was first characterized in great detail, especially withregard to its manifold pharmacological effects (Frey et al., 1950). Werle also observed for the first time irreversible ‘fermental degradation’ of kallidin by ‘kininases’ and identified them as peptidases (Werle and Grunz, 1939). Therefore, the fundamental knowledge of the system that we refer to today as the kallikrein-kinin system (cascade) was provided by Frey, Kraut and Werle.

The vital importance of the kallikrein-kinin system for basic mechanisms in biochemistry, patho/physiology, pharmacology and more recently, molecular biology and cell biology, and the great interest and practical benefit of the system to clinical medicine, has stimulated scientists from various disciplines worldwide to become involved in kallikrein-kinin research. Among them are scientists working also on various regulatory or mediator systems that interact with the kallikrein-kinin cascade. A drug based on the seminal research designated as angiotensin I converting enzyme (ACE)inhibitor has been shown to be of immense value in the treatment of coronary heart disease. This drug simultaneously blocks the ACE-catalyzed degradation of kinins and the generation of angiotensin II, two tissue hormones that exhibit opposite biological or pharmacological effects.



Frey, E.K. (1926): Zusammenhänge zwischen Herzarbeit und Nierentätigkeit. Arch. Klin. Chir. 142, 663 - 669.

Frey, E.K. and Kraut, H. (1926): Über einen von der Niere ausgeschiedenen, die Herztätigkeit anregenden Stoff. Hoppe-Seyler's Z. Physiol. Chem. 157, 32 - 61.

Frey, E.K, Kraut, H. and Werle, E., eds. (1950): Kallikrein-Padutin. F. Enke-Verlag, Stuttgart, Germany.

Kraut, H., Frey, E.K. and Werle, E. (1930): Über die Inaktivierung des Kallikreins. Hoppe-Seyler' s Z. Physiol. Chem. 192, 1 - 21.

Werle, E., Götze, W., Kappler, A. (1937): Über die Wirkung des Kallikreins auf den isolierten Darm und über eine neue darmkontrahierende Substanz. Biochem. Z. 289, 217 - 233.

Werle, E. and Grunz, M. (1939): Zur Kenntnis der darmkontrahierenden, uterus-erregenden und blutdrucksenkenden Substanz DK. Biochem. Z. 301, 429 - 436.




Das Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten beherbergt die August-Lenz-Stiftung.